Cofoe Medical Technology (301087) Q3 2025 earnings summary

Executive summary

• Q3 revenue rose 30.72% YoY to ¥902.0M; net income attributable to shareholders increased 38.68% to ¥92.8M. For 9M, revenue grew 6.63% to ¥2.398B and attributable net income rose 3.30% to ¥260.2M.

• 9M operating cash flow increased 35.36% YoY to ¥590.0M, supported by higher cash receipts from product sales and lower payments for materials and goods.

Financial highlights

• Q3 adjusted net income, excluding non-recurring items, was ¥85.8M, up 62.68% YoY; 9M adjusted net income was ¥222.0M, up 1.46%.

• 9M operating revenue was ¥2.398B versus ¥2.249B a year earlier; total operating costs were ¥2.141B versus ¥1.973B.

• 9M net income attributable to shareholders was ¥260.2M versus ¥251.9M; consolidated net income was ¥259.5M.

Key financial ratios and metrics

• Q3 basic and diluted EPS were both ¥0.46, up 39.39% YoY; 9M basic EPS was ¥1.28, up 3.23%, and diluted EPS was ¥1.27, up 3.25%.

• Weighted-average ROE was 1.90% for Q3, up 0.57 percentage points YoY, and 5.29% for 9M, up 0.27 percentage points.

• Period-end total assets were ¥6.540B, up 1.83% from year-end; equity attributable to shareholders was ¥4.714B, down 1.73%.